After Covid-19, Hepatitis A Outbreak in Kerala: What Are The Symptoms And Causes
Kerala is currently witnessing a sharp rise in hepatitis A infections in Avoly and nearby panchayats in Muvattupuzha, around 47 km from the city. The Health authorities have confirmed around 50 cases so far. The first case was reported on May 30. The incubation period for hepatitis A is two to six weeks, therefore, health authorities expect more cases to surface in the coming days.
Most infected individuals attended a wedding at Nadukkara ward in Avoly panchayat on May 3. The authorities suspect that contaminated food and water served at the function may have triggered the outbreak. Around 150 people from Avoly, Manjalloor and Arakuzha panchayats in Muvattupuzha and Idukki and Alappuzha districts attended the event.
Hepatitis A: Causes, symptoms and more
Hepatitis A is a highly contagious liver infection that usually spreads from contaminated food or water or close contact with an infected person or object. Hepatitis viruses cause liver inflammation and affect your liver's ability to function.
What are the symptoms of hepatitis A?
Hepatitis A symptoms can include:
Fever
Loss of appetite
Diarrhea
Tiredness and weakness
Abdominal discomfort
Dark-coloured urine
Jaundice
Joint pain
Itchy skin
Not everyone who is infected will have all the symptoms. Symptoms are typically mild and go away in a few weeks. However, in some cases, symptoms can last for several months and even lead to severe illness.
How to prevent
Vaccination against hepatitis A is one of the most effective ways to prevent it. The vaccine is typically given in two shots. The first shot is followed by a booster shot. Other preventive measures include:
Avoid raw and undercooked meat and fish
Wash fruits and vegetables thoroughly and avoid pre-cut fruits and vegetables.
Practice good hygiene, especially after using the toilet or changing a diaper and before preparing food or eating
Ensure adequate supplies of safe drinking water
Use of safer sex practices
According to the World Health Organisation, most individuals recover fully from hepatitis A with lifelong immunity. However, a very small proportion of people infected with hepatitis A could die from fulminant hepatitis.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
17 hours ago
- NDTV
After Covid-19, Hepatitis A Outbreak in Kerala: What Are The Symptoms And Causes
Kerala is currently witnessing a sharp rise in hepatitis A infections in Avoly and nearby panchayats in Muvattupuzha, around 47 km from the city. The Health authorities have confirmed around 50 cases so far. The first case was reported on May 30. The incubation period for hepatitis A is two to six weeks, therefore, health authorities expect more cases to surface in the coming days. Most infected individuals attended a wedding at Nadukkara ward in Avoly panchayat on May 3. The authorities suspect that contaminated food and water served at the function may have triggered the outbreak. Around 150 people from Avoly, Manjalloor and Arakuzha panchayats in Muvattupuzha and Idukki and Alappuzha districts attended the event. Hepatitis A: Causes, symptoms and more Hepatitis A is a highly contagious liver infection that usually spreads from contaminated food or water or close contact with an infected person or object. Hepatitis viruses cause liver inflammation and affect your liver's ability to function. What are the symptoms of hepatitis A? Hepatitis A symptoms can include: Fever Loss of appetite Diarrhea Tiredness and weakness Abdominal discomfort Dark-coloured urine Jaundice Joint pain Itchy skin Not everyone who is infected will have all the symptoms. Symptoms are typically mild and go away in a few weeks. However, in some cases, symptoms can last for several months and even lead to severe illness. How to prevent Vaccination against hepatitis A is one of the most effective ways to prevent it. The vaccine is typically given in two shots. The first shot is followed by a booster shot. Other preventive measures include: Avoid raw and undercooked meat and fish Wash fruits and vegetables thoroughly and avoid pre-cut fruits and vegetables. Practice good hygiene, especially after using the toilet or changing a diaper and before preparing food or eating Ensure adequate supplies of safe drinking water Use of safer sex practices According to the World Health Organisation, most individuals recover fully from hepatitis A with lifelong immunity. However, a very small proportion of people infected with hepatitis A could die from fulminant hepatitis.
Time of India
17 hours ago
- Time of India
Japan introduces universal artificial blood that helps save lives; here's how
Source: The Japan Times Japanese scientists have developed a universal artificial blood substitute that can revolutionize global healthcare and address critical blood shortage challenges. Artificial blood is an invention, which serves as a substitute for real blood. With the World Health Organisation (WHO) highlighting a global blood shortage, this innovation could play a very crucial role in saving lives during trauma, surgeries, emergencies, and other medical procedures, if proven successful. If the clinical trials prove successful, Japan could become the first-country to deploy artificial blood for real-world medical care by 2030. Japan creates virus-free artificial blood that can be stored for years Professor Hiromi Sakai at Nara Medical University has pioneered this approach, creating stable, virus-free artificial red blood cells that eliminate the need for blood type matching. According to The Japan Times, artificial red blood cells are produced by extracting hemoglobin, which carries oxygen, from donated blood and wrapping it with an artificial lipid membrane, according to the team. The artificial cells have a purplish color, unlike the common red color of blood, as they are made in a way that they do not oxidize until they are used The artificial blood technology centers on hemoglobin vesicles, small artificial blood cells that extract hemoglobin, the oxygen-carrying molecule, from expired donor blood and encase it in protective shells. Artificial blood offers several benefits over traditional blood donations. It eliminates the need for compatible testing, making it very useful in emergency situations, and can be stored at room temperature for up to two years, far exceeding the short shelf life of donated blood. Revolutionizing global healthcare This technology could improve healthcare by eliminating the compatibility issues and blood shortages especially in remote areas where blood storage and matching are challenging. Unlike donated blood, these artificial cells have no blood type, eliminating the need for compatibility testing and making them valuable in emergencies. It represents a significant humanitarian breakthrough, promising to ensure blood availability anywhere, anytime, and transforming global healthcare systems. Trial design The trial will initially focus on testing safety before moving to broader performance and efficacy targets. It will administer 100 to 400 milliliters of artificial blood on volunteers. The research represents rapid progress of Japan's artificial blood development program. Their program began with small-scale studies demonstrating that these tiny artificial cells could safely deliver oxygen as normal blood cells do. Also read | 3,500-year-old grave reveals: change in bronze age history around 1500 BC in Central Europe
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate
Bharat Biotech on Thursday announced its partnership with UK-based pharma company GSK for the development and potential use of the Shigella vaccine candidate altSonflex1-2-3. As part of the agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement and large-scale manufacturing. GSK, on the other hand, will support the programme by assisting with clinical trial design, securing external funding and contributing to the access and delivery plans and commercialisation strategy. The company said that the agreement marks a significant step in advancing the vaccine, which targets shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five years of age in low- and middle-income countries (LMICs). 'The vaccine candidate has already demonstrated a strong safety and immunogenicity profile in both European and African trials, including in the primary target population of nine-month-old infants,' it added. Commenting on the development, Krishna Ella, Executive Chairman at Bharat Biotech, said that with no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on LMICs. 'This collaboration combines our strengths in innovation, manufacturing and global health commitment.' According to the World Health Organisation (WHO), Shigella was the second-leading cause of diarrhoeal mortality in 2016 (latest data) among all ages and the leading bacterial cause of diarrhoea, accounting for approximately 212,000 deaths and about 13 per cent of all diarrhoea-associated deaths. The disease is a major contributor to child morbidity and mortality, and the emergence of drug-resistant strains underscores the urgent need for a preventive vaccine. The standard of care for shigellosis primarily involves managing dehydration and using antibiotics. While mild cases often resolve with rest and fluid replacement, more severe cases or those with weakened immune systems may benefit from antibiotics like ciprofloxacin or azithromycin. Thomas Breuer, Chief Global Health Officer at GSK, said that by helping reduce illness and antibiotic use, this vaccine has the potential to play a critical role in combating antimicrobial resistance (AMR). The companies claimed that the vaccine candidate has broad serotype coverage, an innovative Generalised Modules for Membrane Antigens (GMMA)-based platform and robust early clinical results. 'GMMA technology is a platform that uses bacterial outer membranes to deliver the O antigen to the immune system, allowing for high-yield production, which creates affordable vaccines for underserved populations,' they added in a statement.
